Payment overview · 2025
General Payments
$872.80
41 reported records · 13 companies
Healthcare provider profile · identity verified
Brindha Suresh, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · AURORA, CO · NPI 1992752349
Verified facts
What the public records show
CMS Open Payments records show Brindha Suresh, M.D. received $872.80 in general payments during 2025 across 41 reported records.
Exact Sciences Corporation accounted for 23.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 25 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Ozempic, Paxlovid, Rybelsus, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Synthroid by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 73 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 73 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 78 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $200.50 | 23.0% | 10 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $179.13 | 20.5% | 10 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $92.92 | 10.7% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $81.76 | 9.4% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $81.61 | 9.3% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $48.69 | 5.6% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $39.19 | 4.5% | 2 | 2025 |
| Edwards Lifesciences Corporation | Unresolved — no canonical attribution shown | $32.74 | 3.8% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $30.74 | 3.5% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $23.56 | 2.7% | 1 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $22.27 | 2.5% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $21.71 | 2.5% | 1 | 2025 |
| Zimmer Biomet Holdings, Inc. | Unresolved — no canonical attribution shown | $17.98 | 2.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $872.80 | 41 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $139.40 | 7 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $103.59 | 5 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $65.31 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $60.72 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $60.70 | 3 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $48.69 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $39.19 | 2 | 2025 |
Source payment records
|
|||||
| EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Normalized: edwards sapien 3 transcatheter heart valve thv |
Device | Edwards Lifesciences Corporation | $32.74 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $30.74 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $27.61 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $27.61 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $23.56 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $23.56 | 1 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $22.27 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $21.71 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $21.71 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $19.43 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $19.30 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $18.62 | 1 | 2025 |
Source payment records
|
|||||
| Gel-One Cross-linked Hyaluronate Normalized: gel one cross linked hyaluronate |
Device | Zimmer Biomet Holdings, Inc. | $17.98 | 1 | 2025 |
Source payment records
|
|||||
| Persona Normalized: persona |
Device | Zimmer Biomet Holdings, Inc. | $17.98 | 1 | 2025 |
Source payment records
|
|||||
| ROSA Normalized: rosa |
Device | Zimmer Biomet Holdings, Inc. | $17.98 | 1 | 2025 |
Source payment records
|
|||||
| mymobility Platform Normalized: mymobility platform |
Device | Zimmer Biomet Holdings, Inc. | $17.98 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $15.99 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $15.99 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 73 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 78 | exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 13 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 28 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
73 | 18 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
73 | 18 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
78 | 15 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
13 | 13 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 407 | 121 |
| Atorvastatin Calcium | Atorvastatin Calcium | 342 | 102 |
| Levothyroxine Sodium | Levothyroxine Sodium | 303 | 80 |
| Losartan Potassium | Losartan Potassium | 247 | 73 |
| Metformin Hcl Er | Metformin Hcl | 210 | 60 |
| Lisinopril | Lisinopril | 196 | 55 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 195 | 63 |
| Simvastatin | Simvastatin | 149 | 41 |
| Pantoprazole Sodium | Pantoprazole Sodium | 128 | 37 |
| Omeprazole | Omeprazole | 125 | 39 |
| Hydrochlorothiazide | Hydrochlorothiazide | 106 | 35 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 99 | 24 |
| Gabapentin | Gabapentin | 98 | 39 |
| Metformin Hcl | Metformin Hcl | 88 | 26 |
| Ezetimibe | Ezetimibe | 85 | 24 |
| Ozempic | Semaglutide | 78 | 15 |
| Metoprolol Succinate | Metoprolol Succinate | 77 | 25 |
| Escitalopram Oxalate | Escitalopram Oxalate | 76 | 22 |
| Trazodone Hcl | Trazodone Hcl | 76 | 19 |
| Jardiance | Empagliflozin | 73 | 18 |
| Pioglitazone Hcl | Pioglitazone Hcl | 71 | 19 |
| Meloxicam | Meloxicam | 68 | 25 |
| Allopurinol | Allopurinol | 61 | 18 |
| Tamsulosin Hcl | Tamsulosin Hcl | 55 | 15 |
| Alendronate Sodium | Alendronate Sodium | 52 | 15 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 52 | 14 |
| Prednisone | Prednisone | 51 | 40 |
| Nebivolol Hcl | Nebivolol Hcl | 46 | 15 |
| Tramadol Hcl | Tramadol Hcl | 46 | suppressed |
| Atenolol | Atenolol | 44 | 11 |
| Cefdinir | Cefdinir | 43 | 36 |
| Furosemide | Furosemide | 42 | 14 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 41 | 26 |
| Januvia | Sitagliptin Phosphate | 41 | 12 |
| Sertraline Hcl | Sertraline Hcl | 41 | 15 |
| Bupropion Xl | Bupropion Hcl | 39 | 11 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 38 | suppressed |
| Cephalexin | Cephalexin | 36 | 26 |
| Hydralazine Hcl | Hydralazine Hcl | 36 | 11 |
| Duloxetine Hcl | Duloxetine Hcl | 34 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 33 | 12 |
| Glipizide | Glipizide | 33 | suppressed |
| Mirtazapine | Mirtazapine | 33 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 31 | 24 |
| Metoprolol Tartrate | Metoprolol Tartrate | 31 | 11 |
| Montelukast Sodium | Montelukast Sodium | 30 | 11 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 29 | 18 |
| Valsartan | Valsartan | 29 | suppressed |
| Carvedilol | Carvedilol | 28 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 28 | suppressed |
| Eliquis | Apixaban | 28 | suppressed |
| Methylprednisolone | Methylprednisolone | 28 | 23 |
| Rybelsus | Semaglutide | 28 | suppressed |
| Famotidine | Famotidine | 27 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 27 | suppressed |
| Synthroid | Levothyroxine Sodium | 27 | suppressed |
| Azithromycin | Azithromycin | 25 | 22 |
| Paroxetine Hcl | Paroxetine Hcl | 25 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 24 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 23 | 14 |
| Fluticasone Propionate | Fluticasone Propionate | 23 | suppressed |
| Nifedipine Er | Nifedipine | 23 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 22 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 21 | 12 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 21 | 13 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 20 | 13 |
| Finasteride | Finasteride | 19 | suppressed |
| Trulicity | Dulaglutide | 19 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 18 | suppressed |
| Colchicine | Colchicine | 17 | suppressed |
| Levofloxacin | Levofloxacin | 17 | 12 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 17 | suppressed |
| Spironolactone | Spironolactone | 17 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 17 | suppressed |
| Gemfibrozil | Gemfibrozil | 15 | suppressed |
| Ibuprofen | Ibuprofen | 15 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 15 | suppressed |
| Acyclovir | Acyclovir | 14 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 14 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 13 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 13 | 13 |
| Sotalol | Sotalol Hcl | 13 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 13 | suppressed |
| Amoxicillin | Amoxicillin | 12 | 12 |
| Eletriptan Hbr | Eletriptan Hydrobromide | 12 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 12 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 12 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 12 | suppressed |
| Lovastatin | Lovastatin | 12 | suppressed |
| Potassium Chloride | Potassium Chloride | 12 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 12 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 12 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 12 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 12 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 12 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 12 | suppressed |
| Xarelto | Rivaroxaban | 12 | suppressed |
| Fluconazole | Fluconazole | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $872.80 · 41 records | Exact Sciences Corporation | AIRSUPRA, AREXVY, BREZTRI, CAPVAXIVE, Cologuard Collection Kit, EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV), FREESTYLE LIBRE 3, GARDASIL 9, Gel-One Cross-linked Hyaluronate, JARDIANCE, MOUNJARO, NURTEC ODT, NUZYRA, Ozempic, PAXLOVID, Persona, ROSA, Rybelsus, SHINGRIX, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, VRAYLAR, Wegovy, ZEPBOUND, mymobility Platform | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error